Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (MASI) delivers innovative noninvasive monitoring technologies and premium audio solutions across global markets. This news hub provides investors and industry professionals with timely updates directly from corporate communications and verified financial sources.
Access official press releases covering Masimo's healthcare innovations, including sensor technology advancements and hospital automation systems, alongside developments in its consumer audio division. Our repository tracks regulatory filings, partnership announcements, and clinical validation studies while maintaining strict editorial neutrality.
Key updates include quarterly earnings disclosures, product launch details across both business segments, and strategic corporate actions. Bookmark this page for streamlined monitoring of Masimo's operational milestones and market-moving events in the medical technology sector.
Masimo (NASDAQ: MASI) and Denon have launched the White PerL and PerL Pro earbuds, promising cutting-edge personalized audio. Featuring Masimo’s Adaptive Acoustic Technology (AAT), these earbuds tailor sound based on individual hearing profiles, enhancing depth, detail, and clarity. Denon's legacy of audio excellence combines with Masimo's innovation for a superior listening experience. The earbuds offer active noise cancellation, social mode, and, in the Pro model, spatial audio and adaptive noise cancellation. Available now, the Denon PerL is priced at $199, and the PerL Pro at $349.
Masimo (NASDAQ: MASI) will present at the BofA Securities Health Care Conference on May 15, 2024. A live webcast will be available on their website.
Masimo reported strong financial results for the first quarter of 2024 with consolidated revenue at $492.8 million, including healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. GAAP net income per diluted share was $0.35 and Non-GAAP net income per diluted share was $0.77. The company saw improvements in gross margins in healthcare and is increasing guidance for healthcare revenues and EPS for 2024. Masimo also announced plans to separate its consumer business.
Masimo, a global leader in monitoring technologies, received FDA clearance for Stork™, an over-the-counter baby monitoring system for infants up to 18 months. The system provides continuous monitoring of oxygen saturation, pulse rate, and skin temperature without a prescription. It offers visual and audible alarms if readings fall outside preset ranges, utilizing advanced pulse oximetry technology. Stork is available at major retailers and online, with additional alarm features through a mobile app update. Stork features a sleek design, patented SET® sensor technology, and a camera with future AI-based features. It is FDA-cleared for OTC use, suitable for infants and neonates in home environments.
FAQ
What is the current stock price of Masimo (MASI)?
What is the market cap of Masimo (MASI)?
